Please assess the completion status of the following clinical trial:

Trial Title: Collagenase Option for Reduction of Dupuytren's Contracture in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 20 years old when written informed consent is obtained.~* Having a diagnosis of Dupuytren's contracture and flexion contracture due to palpable cord in at least 1 non-thumb finger (20° to 100° in MP joint and 20° to 80° in PIP joint).~* Positive tabletop test result (i.e., cannot simultaneously place affected finger and palm on a table).~* Voluntary written informed consent is obtained.~Exclusion Criteria:~Patients meeting any of the following criteria will be excluded:~* Is pregnant, may be pregnant, wishes to become or could become pregnant during the study (i.e., unless acceptable contraception is used, the patient has been sterilized, or the patient is postmenopausal \[no menstrual period for at least 12 months without any other medical cause\]), or is breastfeeding.~* Has a coexisting chronic disease of the hand that could impact assessment (muscular disease, neurological disease, neuromuscular disease).~* Has received another investigational product 30 or fewer days before first injection of the investigational product.~* Has undergone aponeurectomy, aponeurotomy, needle aponeurotomy/fasciotomy, verapamil/interferon injection, or another Dupuytren's Contracture treatment of the primary joint 90 or fewer days before first injection of the investigational product.~* Is allergic to collagenase or any of the excipients of AK160.~* Has taken tetracycline derivative such as minocycline and doxycycline 14 or fewer days before first injection of the investigational product.~* Has received a collagenase product 30 or fewer days before first injection of the investigational product.~* Is currently taking or has taken, 7 or fewer days before first injection of the investigational product, an anticoagulant or antiplatelet drug (other than ≤150 mg/day of aspirin).~* Has suffered a recent stroke, hemorrhage, or other disease affecting the hands.~* Has a serious disease unsuited for the study.~* Receiving treatment for a malignancy.~* History of drug or alcohol addiction within the past 5 years or history of drug or alcohol abuse within the past year.~* Has received previously the investigational product (AK160, AA4500, XIAFLEX®, or XIAPEX®).~* Otherwise found ineligible as a subject by the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AK160 0.58 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).